Injectable Drug Delivery - Advances in Drug Delivery, Injection Devices and Technology (Conference, London)
DUBLIN, Mar. 20, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/sq2qm5/injectable_drug) has announced the addition of the "Injectable Drug Delivery - Advances in Drug Delivery, Injection Devices and Technology (Conference, London)" conference to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769)
The Injectable Drug Delivery Conference will be held on the 26th & 27th March 2014 at Le Meridien Hotel, Piccadilly, London
KEY TOPICS TO INCLUDE:
- Market trends
- Human factors and useability
- Fluid dynamics - modelling the realities of injection performance
- Delivery of high viscosity drugs
- Case study presentation on devices in development
- Latest self injection trends
- Development of a parenteral device
- Delivery of high volumes
- Compliance modelling and parenteral drug delivery
- The insulet drug delivery system
DATES:
26 & 27 March 2014
TIMES:
Day One: 26 March 2013
Start times: 9.30 Finish 17.45
Drinks Reception Followed by Dinner 19.30
Day Two: 27 March 2013
Start times: 9.00 Finish 16.15
VENUE FOR CONFERENCE AND DINNER:
Le Meridien Hotel, Piccadilly, London
NOTE: Please note that there is a Pre-conference seminar on 25th March on 'Prefilled Syringes - Advances in Manufacture' and also a Post Conference Workshop on 28th March on 'Human Factors and Usability Engineering in the development of drug delivery products'.
Events may be cancelled due to commercial or organisational reasons. In this case Research and Markets will refund all registration fees which have already been paid. Research and Markets will not refund any charges arising from the participant having to cancel or re-book transportation or accommodation which he or she has arranged
Key Topics Covered:
INJECTABLE DRUG DELIVERY DAY ONE - 26 March 2013
09.30 - Chairman's Welcome and Introduction
Dr Gregory Berman,
Head of Innovation and Technology Management Group, Sagentia, UK
09.40 - Key Note Address: Market Trends
- High concentration formulations
- Larger doses, less frequent injections
Mathias Romacker, Drug Delivery Devices and Business Development, Amgen, USA
10.20 - Human Factors and Useability
- Ethonographic research on atuoinjector use for chronic conditions
- Relationship between a disease and its therapy - emotional and functional levels
- How this affects device selection
Mathew Young, CEO, Oval Medical Technologies Ltd, UK
11.00 - Discussion followed by Coffee
11.30 - Fluid Dynamics - Modelling the Realities of Injection Performance
- Mathematical modelling enables the opportunities and challenges of a range of device types to be explored early
- The implications of such characteristics as viscosity, dose volume and injection frequency are inseparable from the choice of delivery device
- Unfortunately, early consideration of the delivery device does not always take place. Opportunities can thus be lost and problems created which are costly and difficult to solve later
- Mathematical modelling techniques, applied properly, improve understanding of the issues concerned and enable better and earlier decisions to be taken
- Better informed decisions and better appreciations of the design options in turn support device designs which are better for the end user
- Early understanding of device issues supports and enables robust designs and capable manufacture
- Early understanding can shorten development timescales, in turn making earlier approval and earlier revenues possible
Andy Fry, Founder, Team Consulting, UK
12.10 - Delivery of High Viscosity Drugs
- Device formats
- Overcoming the challenges
Speaker, (invited)
12.50 - Discussion followed by Lunch
14.10 - Mixing Technologies for Reconstitution Devices
- Market Needs - Industry drivers and demands for these types of devices
- Latest mixing technologies
- Comparison of Lyophilised and Spray drying technologies
- Technical challenges with these types of devices
Tom Bailey, Managing Director, 3PInnovation, UK
14.50 - Device Case Study
Ian Anderson, Innovation Director, Bespak UK (invited)
15.30 - Discussion followed by Tea
16.10 - Latest Self Injection Trends
- General market trends
- Trends for biologics
- Trends for generics
- Pre-configured devices
- Future outlook
Mats Persson, Managing Director, SHL Group, Sweden
16.50 - Innovation in Primary Container Materials
- Trends for user requirements intended for self injection
- Material technology options and selection criteria
- Integration of Quality by Design for components
- Platform approach for lifecycle management
Tibor Hlobik, West Pharmaceutical Services
17.30 - Discussion
17.45 - End of Day One
19.30 - Drinks Reception Followed by Dinner at Le Meridien Hotel, London
INJECTABLE DRUG DELIVERY DAY TWO - 27 March 2013
09.00 - Review of Day One
Dr Gregory Berman,
Head of Innovation and Technology Management Group, Sagentia, UK
09.10 - What Does Pharma Want From its Drug Delivery Suppliers
Nick Bowman, Senior Director, Head of Devices COE, Pfizer, UK
09.50 - Pump Technology Case Study
Jonathan Rigby, President & CEO, SteadyMed Therapeutics Inc, USA, (invited)
10.30 - Discussion followed by Coffee
11.10 - Compliance Monitoring and Parenteral Drug Delivery
- Why is the industry suddenly talking about compliance and adherence monitoring (clinical trials and commercial applications)
- Advances in wireless communications enabling intelligent compliance monitoring
- The widespread availability of smart devices and their use in compliance monitoring, adherence and patient education
- Use of smartphone / smart devices apps for providing real-time information display and the potential for two way communications with the patient
- Regulatory issues associated with connected health systems and smartphone apps
- Using the cloud to store and disseminate data securely
Mark Tuckwell, Senior Consultant, Connected Health Systems,
Sagentia, UK
11.50 - Wireless Communication and Electronics for Compliance Monitoring
- Patient therapy compliance continues to be one of the biggest challenges in health systems
- 50% of all patients do not complete required treatment
- Reasons for the high rate of non-compliance
- Opportunities for medical manufacturers to offer innovative solutions
- Electronic compliance aids open interesting possibilities to remind, monitor and track patients' behavior, as well as to share vital therapy information with healthcare providers
- Key technologies that facilitate compliance, ranging from low-cost disposable electronics for dose counts and logs to a complete cloud-based system for monitoring compliance
Lior Shtram, Director, Design & Engineering, Flextronics Medical, Israel
12.30 - Discussion followed by Lunch
14.00 - Update on Regulations and Standards
Lee Leichter, President P/L Medical, USA
14.40 - The Insulet Drug Delivery System
Consists of two components
- Drug Delivery Pod
- Drug Delivery Manager
A Programmable, body worn, disposable, subcutaneous infusion pump
- Delivers up to 2ml of drug product over a three day period
- Delivery rate from 0.5 to 300 µl/hr
- Automated catheter insertion
- Waterproof (IPX8 25 feet for up to 60 minutes)
Provides the HCP and user maximum control, versatility, comfort and safety, while overcoming the numerous drawbacks of conventional infusion pump systems
Kevin Schmid, Vice President, Business Development & Advanced Technology Insulet Corporation, USA
15.20 - The Rise of the Bolus Injector
The changing needs of patients and new drugs are driving the growth of a new class of injection device: the large volume' or bolus' injector. This presentation will report the findings of a new research project run in collaboration with the Judge Business School, covering:
- The changing needs of patients and new drugs
- Could autoinjectors and infusion pumps meet the needs?
- Bolus injectors: a new class of injection device
- Example devices
- What to expect from the draft standard ISO 11608-6' on bolus injectors.
Tom Oakley, Director of Drug Delivery Device Development, Springboard, UK
16.00 - Discussion and Chairman's Closing Remarks
16.15 - End of Conference and Tea
For more information visit http://www.researchandmarkets.com/research/sq2qm5/injectable_drug
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article